Deka Biosciences, Inc

📍 Germantown, United States👥 42 employees💰 Last funded Jun 2023
Biotechnology Research🌐 dekabiosciences.com
Website LinkedIn
Deka Biosciences, Inc., is an early-stage biotechnology company focused on generating the next generation targeted cytokine therapies to treat cancer and inflammatory diseases. Deka is developing the dual cytokine, (DiakineTM) platform. Diakines are comprised of optimized, stimulatory, or suppressive disease specific IL-10 variants coupled to other stimulatory or suppressive cytokines via a T1/2 life extending tissue targeting, non-immunogenic scFv technology.
3
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
United States
2
Canada
1
Investor activity2021–2023 · investors recorded per year
2021220231
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Deka Biosciences, Inc?
Deka Biosciences, Inc has 3 investors on record on gritt.io.
When did Deka Biosciences, Inc last raise funding?
The most recent investment in Deka Biosciences, Inc recorded on gritt.io was in June 2023.
What industry is Deka Biosciences, Inc in?
Deka Biosciences, Inc operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Deka Biosciences, Inc based?
Deka Biosciences, Inc is headquartered in Germantown, United States.